secwatch.observer — SEC 8-K summary
======================================

Issuer:     NUTRA PHARMA CORP (—)
CIK:        0001119643
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001493152-24-010998
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 5.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nutra Pharma CEO Rik Deitsch resigns amid SEC settlement; Dr. Michael Flax appointed CEO/CFO/Chairman
--------------------------------------------------------------------------------

- Rik Deitsch resigned as CEO, Director, Chairman, and CFO effective March 19, 2024, due to SEC settlement.
- SEC settlement permanently enjoins company, Deitsch, and McManus from securities law violations; 3-year officer/director and penny stock bars for Deitsch.
- Disgorgement and civil penalties for all defendants, and a possible penny stock bar for McManus, left for later court resolution.
- Dr. Michael Flax appointed CEO, CFO, and Chairman effective March 20, 2024; previously served as CEO of Nutra Pharma from 2001-2002.
- Rik Deitsch remains as Operations Manager, reporting to VP of Operations Joe Lucas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1119643/000149315224010998/0001493152-24-010998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1119643/000149315224010998/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer